Regenxbio Inc at Piper Sandler Healthcare Conference Transcript
Good morning, everyone. My name is Swapnil Malekar. I am one of the biotech analysts here at Piper Sandler. It is with great pleasure that I want to introduce Ken Mills, who is the CEO of REGENXBIO, a very interesting gene therapy company working in different indications, with lead asset and several retinal and eye indications. So, Ken?
Swapnil, thank you. Thanks to Piper for the invitation and for the continued support. Enjoying today to have the opportunity in person to present information about our company, REGENXBIO. There will be -- the lawyers tell me to be careful about forward-looking statements. But to the extent that I slip, we've got SEC documents that will back us up.
The mission of REGENXBIO is seeking to improve lives through the curative potential of gene therapy. We are an in vivo gene therapy company using AAV technology. The history of the company is that in the mid- to late-2000s, there was buy-ins that were done that we thought were
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
